Publication Details (including relevant citation information):
A. Newan, E. Munson. Amer. Pharm. Rev.2012, April, 92-98
Amorphous solid dispersions are being used more frequently in the pharmaceutical industry to address bioavailability problems with poorly soluble drugs. Since amorphous dispersions are inherently metastable, there is always a possibility that the drug will convert to the more stable crystalline form, resulting in decreased bioavailability. One way to increase confidence that the material will not recrystallize is to ensure that the drug and polymer are miscible. In this article some important methods used to characterize drug-polymer miscibility are described and evaluated.